TP53 and neoplasm: Recent studies in DIPGs have demonstrated that direct PPM1D inhibitor GSK2830371 inhibits p53 wild-type tumor cells growth and sensitizes cells to PARP inhibition and radiation through the re-activation of p53 pathway.